Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Sponsor
Centre Hospitalier Universitaire de Nice
Study ID
NCT07074418
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.

Key Dates

Start date
Apr 30, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
34 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group 1
    empaglifozine 10mg / wash-out / matching placebo
  • Active Comparator: Group 2
    matching placebo / wash-out / empaglifozine 10mg

Primary Outcome Measure

Anti-proteinuric effect [ Time Frame: 20 months ]

Central Contacts

Related Studies